Lv52
1480 积分 2023-04-17 加入
Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents
10天前
已完结
Screening for Latent Tuberculosis Infection in Adults
10天前
已完结
De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials
21天前
已完结
Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention
21天前
已完结
Sex differences in the metabolic activation of and platelet response to vicagrel in mice: Androgen as a key player
21天前
已关闭
A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata
1个月前
已完结
Statistical Consideration and Challenges in Bridging Study of Personalized Medicine
1个月前
已完结
Vitiligo
3个月前
已完结
Vitiligo
3个月前
已完结
Implementation of the vitiligo area scoring index in clinical studies of patients with vitiligo: a scoping review
3个月前
已完结
皖公网安备34019202002308
